Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Mink Therapeutics Inc (INKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INKT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.42% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.57M USD | Price to earnings Ratio - | 1Y Target Price 48.33 |
Price to earnings Ratio - | 1Y Target Price 48.33 | ||
Volume (30-day avg) 10092 | Beta 0.16 | 52 Weeks Range 4.56 - 19.00 | Updated Date 04/2/2025 |
52 Weeks Range 4.56 - 19.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.86 |
Earnings Date
Report Date 2025-03-18 | When - | Estimate -0.5 | Actual -0.62 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -137.35% | Return on Equity (TTM) -1238.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36917706 | Price to Sales(TTM) - |
Enterprise Value 36917706 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.67 | Shares Outstanding 3966390 | Shares Floating 1008812 |
Shares Outstanding 3966390 | Shares Floating 1008812 | ||
Percent Insiders 74.76 | Percent Institutions 2.08 |
Analyst Ratings
Rating 4.67 | Target Price 6.5 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mink Therapeutics Inc
Company Overview
History and Background
Mink Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer. Founded in 2017, it went public via IPO on October 19, 2021.
Core Business Areas
- iNKT Cell Therapies: The company's core business revolves around developing and commercializing iNKT cell therapies for solid tumors and hematologic malignancies. Their core technology involves engineering iNKT cells to target specific cancer antigens.
Leadership and Structure
Dr. Jennifer Buell is the Chief Executive Officer. The company operates with a scientific advisory board composed of experts in immunology and oncology.
Top Products and Market Share
Key Offerings
- ILT-NK Cell Therapy: Mink's lead product candidate, ILT-NK cell therapy, is in clinical development. It is being evaluated in Phase 1 clinical trials for the treatment of solid tumors and hematologic malignancies. Market share data is not applicable at this stage, as the product is still in development. Key competitors in cell therapy include Novartis (NVS), Gilead Sciences (GILD), and Bristol Myers Squibb (BMY), though their technologies differ.
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing sector within the biotechnology industry, driven by advancements in immunotherapy and personalized medicine. It is characterized by high innovation, significant investment, and regulatory scrutiny.
Positioning
Mink Therapeutics aims to differentiate itself through its focus on iNKT cells, which offer a unique approach to cancer immunotherapy. This leverages the iNKT cells' ability to bridge innate and adaptive immunity.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach hundreds of billions USD. Mink is positioned to capture a portion of this TAM focusing on hard to treat solid tumors, as its iNKT-based therapies progress through clinical trials and potentially commercialize.
Upturn SWOT Analysis
Strengths
- Novel iNKT cell therapy platform
- Strong scientific foundation
- Experienced leadership team
- Potential for off-the-shelf cell therapies
Weaknesses
- Early stage clinical development
- Limited clinical data
- High cash burn
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of iNKT cell therapy platform to other disease areas
- Positive clinical trial results
- FDA Fast Track designation
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- CAR T-cell therapy companies.
Competitive Landscape
Mink faces competition from established pharmaceutical companies with broader cell therapy portfolios and resources. However, its iNKT cell therapy platform offers a unique approach that could potentially provide advantages in specific cancer types.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by advancements in clinical trials and milestones achieved in their drug development pipeline.
Future Projections: Future growth depends on the success of clinical trials and the potential for commercialization of their iNKT cell therapy. Analyst estimates vary widely due to the uncertainty inherent in biotech investing.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials and exploring potential partnerships for manufacturing and commercialization.
Summary
Mink Therapeutics is a high-risk, high-reward clinical-stage company with a novel iNKT cell therapy platform. Its success hinges on positive clinical trial results and the ability to secure funding. The company faces strong competition and significant regulatory hurdles, but its unique technology offers potential for addressing unmet needs in cancer treatment.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment in biotech companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mink Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-15 | President, CEO & Director Dr. Jennifer S. Buell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://minktherapeutics.com |
Full time employees 23 | Website https://minktherapeutics.com | ||
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.